1 / 44

Complex Case of an Elderly Patient with AMS, Bradycardia, and Hypotension

Explore a detailed case presentation of an elderly female with AMS, bradycardia, and hypotension, covering protocols, assessment, management, and differential diagnoses. Learn about the complexities and nuances of addressing these critical conditions.

karlah
Download Presentation

Complex Case of an Elderly Patient with AMS, Bradycardia, and Hypotension

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. THE CODE STROKE THAT WASN’T Amy Gutman MD Director of Emergency Medicine

  2. OBJECTIVES • Case presentation • Protocol review • Assessment & management

  3. CASE PRESENTATION • 911 call for “Stroke” at local SNF • 85 yo female, last seen well at breakfast 3 hours earlier • Normally with dementia, but otherwise neurologically intact • Now with AMS, slurred speech

  4. PMH / SOCIAL • PMH • Alzheimer's • Hypertension • Hypercholesterolemia • Social • 40+ PYH, quit x 20 years, (-) ETOH / drugs • Full Code

  5. MEDICATIONS • Haloperidol 5mg po prn • Metoprolol XL 50mg po BID • Atorvastatin 40mg po qDay • Aspirin 81mg po qDay

  6. INITIAL ASSESSMENT • Elderly female, drooling, minimally responsive but maintaining airway • ABC • Maintaining airway, adequate respirations, diminished distal pulses • Vitals • HR 28 RR 10 BP 60/P Sat 92% ra

  7. EMS AMS PROTOCOL

  8. SECONDARY SURVEY • Stroke Scale • Face symmetrical • Speech slurred • Both arms weak • Glucose 58

  9. EKG

  10. ON SCENE • Problems identified • AMS • Bradycardia • Hypotension • Treatments initiated • 1 IV & 200cc NS • 1 amp dextrose • 4mg naloxone • Cardiac monitor • Medical control – called to notify of “Code Stroke 5 minutes out” • At EMS arrival patient remained altered, hypotensive & bradycardic • Let’s discuss…

  11. AMS, BRADYCARDIA, HYPOTENSION • What is the priority? • Once bradycardia & hypotension identified, it’s difficult but important to address both simultaneously • Equally important to start putting together a differential diagnosis as the shock is not going to kill this patient…it’s what’s CAUSING the shock that’s going to kill the patient!

  12. AMS MNEMONIC – AEIOU TIPS • A Alcohol, acidosis, arrythmia • E Encephalopathy, electrolytes, endocrine, environmental • I Insulin • O Opiates, oxygen (hypoxia) • U Uremia • T Trauma, toxins • I Infection, increased ICP • P Psychosis, poisoning (CO, cyanide), porphyria • S Stroke, shock, seizure • But…What Causes AMS, Bradycardia & Hypotension? • CVA w/ increased ICP • Infection • Cardiogenic shock • Potassium • Toxin

  13. AMS, BRADYCARDIA, HYPOTENSION DDX

  14. BRADYCARDIA MANAGEMENT https://www.aclsmedicaltraining.com/adult-bradycardia-algorithm/

  15. HYPOTENSION CAUSES https://www.cvphysiology.com/Blood%20Pressure/BP030

  16. MANAGEMENT: VOLUME, RATE OR PUMP? https://accessemergencymedicine.mhmedical.com/content.aspx?sectionid=41069038&bookid=521

  17. VASOPRESSORS & INOTROPES • Inotropy • Myocardial contractility • Chronotropy • Heat rate • Inotropic agents primary increase heart rate • Vasopressor agents (to varying degrees) increase HR, SVR & CO https://umem.org/educational_pearls/2506/

  18. VASOPRESSORS & INOTROPES • Alpha-1 • Increase arterial tone / MAP & venous tone • Augment cardiac preload  • Beta-1  • Increase inotropy, chronotropy & arterial tone / SVR • Beta-2 & Dopamine • Vasodilation increases increases perfusion to cardiac, renal & GI tissues • V1 • Increase arterial vasoconstriction /  MAP https://umem.org/educational_pearls/2506/

  19. IN THE ED • Patient had seizure then intubated for airway protection • Radiology: • Optic nerve sheath US normal • eFAST normal • Head CT normal • CXR CHF, cardiomegaly • Cardiac US: • Poor EF, right atrial collapse, global wall motion abnormality https://www.grepmed.com/images/1632; http://www.sonomojo.org/keeping-an-eye-on-intracranial-pressure-detecting-elevated-icp-using-ocular-ultrasound/

  20. FURTHER STABILIZATION • Central line placed • Norepinephrine drip • 2 liters lactated ringers • Foley – good UOP • ABG • Combined respiratory alkalosis & metabolic acidosis • Bradycardia resistant to medications • Atropine, glucagon, insulin, glucose had little effect • Transvenous pacemaker placed in ED http://www.tamingthesru.com/blog/procedural-education/transvenous-pacemaker-placement-part-1-the-walkthrough

  21. THE “OH…BY THE WAY” • SNF nurse called the ED 2 hours later with the “Oh…by the way…the patient likely also took her room-mates medications when she got up from the breakfast table. Actually…they sit together at breakfast a lot…..” • Her room-mate’s medications? • Metoprolol XL 100mg • Metformin 500mg • Warfarin 10mg po

  22. SO…NOT A CODE STROKE!

  23. METOPROLOL • Selective β1receptor blocker • Decreases slope of phase 4 action potential • Reduces Na+ uptake & prolongs phase 3 repolarization slowing down K+ release • Lipophilic • No sympathomimetic activity • Weak membrane stabilizing activity • Decreases HR, CO, BP & contractility https://commons.wikimedia.org/wiki/File:Cardiac_action_potential.png

  24. BETA RECEPTORS • B1 • Cardiac, renal, adipose • B2 • Smooth muscle (lungs, peripheral vasculature), cardiac • Vasodilation, bronchodilation • B3 • Adipose, cardiac • Thermogenesis, decrease contractility

  25. CLINICAL SIGNS & SYMPTOMS • Usually within 2 hours, but 95% within 6 hours of Ingestion • Hypotension • Bradycardia • Arrythmias • Seizures • AMS • Bronchospasm • Hypoglycemia

  26. SSX OF BETA BLOCKER OD • Primary organ system affected is cardiovascular • Hallmark of severe toxicity is bradycardia & shock • Selectivity lost in large overdoses

  27. WHY HYPOGLYCEMIA? • Normally heart uses free fatty acids as primary energy source • Switches to carbohydrates / glucose when “stressed” • Glycogenolysis & gluconeogenesis inhibition reduce glucose availability • In addition…this woman took her room-mate’s metformin!

  28. WHY SEIZURES? • Beta-blockers with sodium channel antagonism can cause a wide-complex bradycardia • Wide-complex bradycardia contributes to seizure development • In this patient, likely prolonged QT + hypoglycemia = seizure

  29. POLYPHARMACY • Haloperidol • Metabolized by CYP450 • Worsens AMS • Increases metoprolol effects • Glyburide • Prolonged hypoglycemia • Metformin • Prolonged hypoglycemia • Lactic acidosis • Atorvastatin • CYP450 inducer • Worsens metoprolol effects • Aspirin • Cardioprotective – a positive for this patient • Warfarin • Vitamin K antagonist – made the central line interesting

  30. POLYPHARMACY CONCERNS • Majority of patient’s medications utilize CYP450 system • She was on 2 medications that amplified the effects, increased the duration of action & decreased the elimination of metoprolol • Haloperidol & atorvastatin • Add in her room-mate’s medications (warfarin, glyburide, more metoprolol), & this is a recipe for disaster

  31. BETA BLOCKER OD + POLYPHARMACY MANAGEMENT • Airway stabilization • IVF boluses • Glucagon • Calcium salts • Vasopressors • Insulin + glucose • Lipid emulsion therapy • Sodium bicarbonate + magnesium (occasionally)

  32. SIMULTANEOUS ASSESSMENT & MANAGEMENT • History is incredibly important • Screening labs • ABCs • Intubated & mechanically ventilated • Then address: • Hypotension & bradycardia • Hypoglycemia • Seizures

  33. GLUCAGON • Activates adenylyl cyclase  increases CAMP  increased Ca++ available for muscle contraction • (+) Inotropic & chronotropic effects • Side effects: • Nausea & vomiting from esophageal sphincter relaxation • IV 0.05-0.15 mg/kg (3-10mg) bolus • Effects of IV bolus within 1-2 minutes • Duration of action 10-20 mins requires continuous infusion 1-10 mg/hr

  34. INSULIN THERAPY • Insulin facilitates cardiac utilization of glucose • “Stress” substrate • Glucagon, epinephrine & calcium all promote free fatty acid utilization • 1 unit/kg IV bolus then 0.5-1.0 unit/kg/h continuous infusion

  35. INSULIN THERAPY • Adverse effects include hypoglycemia & hypokalemia • Always give 0.5 gram/kg glucose when initial glucose <400 mg/dL • Q30 minute monitoring of glucose & potassium • Potassium drops precipitously when insulin pushes it into the cell

  36. ADRENERGIC RECEPTOR AGONISTS • Beta-adrenergic receptor agonists improve hypotension • Norepinephrine, dopamine, epinephrine, isoproterenol • Most effective is norepinephrine • Works primarily on Beta 1 receptors • Increases HR & BP

  37. CALCIUM SALTS • In refractory shock to increase inotropy • Calcium chloride has 3 x more elemental calcium than calcium gluconate • 10% gluconate 0.6 mL/kg over 5-10 mins • Then 0.6-1.5 mL/kg/h • 10% chloride 0.2 mL/kg over 5-10 minutes • Then 0.2-0.5 mL/kg/h https://scholarblogs.emory.edu/curbsideconsult/2014/05/09/case-of-the-month-beta-blocker-overdose/

  38. SODIUM BICARBONATE • QRS interval >120 MS • Dose 2-3 mEq/kg of 8.4% NaHCO3 • May repeat boluses

  39. TRANSVENOUS PACING • Electrical capture & restoration of blood pressure https://emedtravel.wordpress.com/2012/04/13/%E2%99%A5-understanding-pacemakers-part-5-of-5/

  40. PHOSPHODIESTERASE INHIBITORS (MILRINONE)? • Limited data • Inhibits breakdown of cAMP by PDE • Maintains intracellular calcium levels • (+) Inotropic effects • No increase in myocardial oxygen demand or HR • Continuous IV infusion of 0.5 micrograms/kg/min

  41. NOT HELPFUL • Atropine • Muscarinic blocker • Unlikely to help or harm • GI decontamination • Activated charcoal of limited benefit within 1-2 hours after ingestion • Whole-bowel irrigation +/- benefit

  42. LAST DITCH OPTIONS • Hemodialysis not an option for metoprolol • Lipid-bound • Intralipid emulsion therapy • Promising, but not standard of care • For intractable hypotension / cardiogenic shock: • ECMO • Intra-aortic balloon pump

  43. REFERENCES • Wax PM et al. beta-blocker ingestion: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila) 2005; 43:131 • Lyden AE, Cooper C, Park E. Beta-Blocker Overdose Treated with Extended Duration High Dose Insulin Therapy. J PharmacolClinToxicol 2014; 2:1015. http://www.jscimedcentral.com/Pharmacology/pharmacology-2-1015.pdf (Accessed on June 16, 2014). • Shepherd et, al. “Treatment of poisoning caused by B-adrenergic and calcium-channel blockers”. Am J Health Syst. Pharm- Vol 63. Oct 1 2006. • Bronstein AC, Spyker DA, Cantilena LR Jr, et al. 2006 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS). Clin Toxicol (Phila) 2007; 45:815. • Bailey B. Glucagon in beta blocker and calcium channel blocker overdoses: a systematic review. Journal of Clinical Toxicology. 2003; 41 (5); 595-602. • Love JN, Howell JM, Litovitz TL, Klein-Schwartz W. Acute beta blocker overdose: factors associated with the development of cardiovascular morbidity. J Toxicol Clin Toxicol 2000; 38:275. • Leppikangas, et al. Levosimendan as a rescue drug in experimental propanolol-induced myocardial depression: a randomized study. Ann Emerg Med. 2009 Dec; 54(6): 811-817. • Vucinić S, Joksović D, Jovanović D, et al. Factors influencing the degree and outcome of acute beta-blockers poisoning. Vojnosanit Pregl 2000; 57:619. • Taboulet P, Cariou A, Berdeaux A, Bismuth C. Pathophysiology and management of self-poisoning with beta-blockers. J Toxicol Clin Toxicol 1993; 31:531.

  44. SUMMARYprehospitalmd@gmail.com / PreparedRescuer.com • When patient can’t give history, rely on what you see with your own eyes • Start resuscitation in the field – if you cannot, notify medical control • Don’t dismiss clinical clues because they do not “fit” your differential • Beware polypharmacy – what you are seeing may be primary or secondary effects of a medical problem or a drug-interaction

More Related